177 related articles for article (PubMed ID: 34010086)
1. Antisense Oligonucleotide Therapy for Ophthalmic Conditions.
Ferenchak K; Deitch I; Huckfeldt R
Semin Ophthalmol; 2021 Aug; 36(5-6):452-457. PubMed ID: 34010086
[TBL] [Abstract][Full Text] [Related]
2. Delivery of Antisense Oligonucleotides to the Mouse Retina.
Garanto A
Methods Mol Biol; 2022; 2434():321-332. PubMed ID: 35213028
[TBL] [Abstract][Full Text] [Related]
3. Emerging Concepts for RNA Therapeutics for Inherited Retinal Disease.
Moore SM; Skowronska-Krawczyk D; Chao DL
Adv Exp Med Biol; 2019; 1185():85-89. PubMed ID: 31884593
[TBL] [Abstract][Full Text] [Related]
4. Antisense Oligonucleotide Therapy for Inherited Retinal Dystrophies.
Gerard X; Garanto A; Rozet JM; Collin RW
Adv Exp Med Biol; 2016; 854():517-24. PubMed ID: 26427454
[TBL] [Abstract][Full Text] [Related]
5. Applications of antisense oligonucleotides for the treatment of inherited retinal diseases.
Collin RW; Garanto A
Curr Opin Ophthalmol; 2017 May; 28(3):260-266. PubMed ID: 28151748
[TBL] [Abstract][Full Text] [Related]
6. RNA therapeutics in ophthalmology - translation to clinical trials.
Gupta A; Kafetzis KN; Tagalakis AD; Yu-Wai-Man C
Exp Eye Res; 2021 Apr; 205():108482. PubMed ID: 33548256
[TBL] [Abstract][Full Text] [Related]
7. AAV-mediated gene therapy for retinal disorders in large animal models.
Stieger K; Lhériteau E; Moullier P; Rolling F
ILAR J; 2009; 50(2):206-24. PubMed ID: 19293463
[TBL] [Abstract][Full Text] [Related]
8. Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension.
Phillips MI
Hypertension; 1997 Jan; 29(1 Pt 2):177-87. PubMed ID: 9039099
[TBL] [Abstract][Full Text] [Related]
9. Advances in AAV vector development for gene therapy in the retina.
Day TP; Byrne LC; Schaffer DV; Flannery JG
Adv Exp Med Biol; 2014; 801():687-93. PubMed ID: 24664759
[TBL] [Abstract][Full Text] [Related]
10. Antisense Oligonucleotide-Based Downregulation of the G56R Pathogenic Variant Causing
Naessens S; Ruysschaert L; Lefever S; Coppieters F; De Baere E
Genes (Basel); 2019 May; 10(5):. PubMed ID: 31083481
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo rescue of aberrant splicing in CEP290-associated LCA by antisense oligonucleotide delivery.
Garanto A; Chung DC; Duijkers L; Corral-Serrano JC; Messchaert M; Xiao R; Bennett J; Vandenberghe LH; Collin RW
Hum Mol Genet; 2016 Jun; 25(12):2552-2563. PubMed ID: 27106101
[TBL] [Abstract][Full Text] [Related]
12. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
[TBL] [Abstract][Full Text] [Related]
13. An Update on Gene Therapy for Inherited Retinal Dystrophy: Experience in Leber Congenital Amaurosis Clinical Trials.
Chiu W; Lin TY; Chang YC; Isahwan-Ahmad Mulyadi Lai H; Lin SC; Ma C; Yarmishyn AA; Lin SC; Chang KJ; Chou YB; Hsu CC; Lin TC; Chen SJ; Chien Y; Yang YP; Hwang DK
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33926102
[TBL] [Abstract][Full Text] [Related]
14. [The application of antisense technology in ophthalmology].
Guo Y; Ge J
Yan Ke Xue Bao; 1998 Jun; 14(2):108-15. PubMed ID: 12580046
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy for inherited retinal diseases: progress and possibilities.
Hu ML; Edwards TL; O'Hare F; Hickey DG; Wang JH; Liu Z; Ayton LN
Clin Exp Optom; 2021 May; 104(4):444-454. PubMed ID: 33689657
[TBL] [Abstract][Full Text] [Related]
16. Retinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications.
Schön C; Biel M; Michalakis S
Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):343-52. PubMed ID: 25615882
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Potential of Tricyclo-DNA antisense oligonucleotides.
Goyenvalle A; Leumann C; Garcia L
J Neuromuscul Dis; 2016 May; 3(2):157-167. PubMed ID: 27854216
[TBL] [Abstract][Full Text] [Related]
18. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.
Oberbauer R
Wien Klin Wochenschr; 1997 Jan; 109(2):40-6. PubMed ID: 9123943
[TBL] [Abstract][Full Text] [Related]
19. Flexible and frozen sugar-modified nucleic acids--modulation of biological activity through furanose ring dynamics in the antisense strand.
Mangos MM; Damha MJ
Curr Top Med Chem; 2002 Oct; 2(10):1147-71. PubMed ID: 12173972
[TBL] [Abstract][Full Text] [Related]
20. Antisense oligonucleotides as therapeutic agents.
Alama A; Barbieri F; Cagnoli M; Schettini G
Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
